Bellerophon Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Craig R. Jalbert CIRA
- Full Time Employees
- 18
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 184 Liberty Corner Road Warren NJ United States of America 07059
- IPO Date
- Feb 13, 2015
- CIK
- 0001600132
- Website
- bellerophon.com
- Similar Companies
- Business
- Bellerophon Therapeutics, Inc. was a clinical-stage biotherapeutics firm that concentrated on creating advanced treatments for cardiopulmonary conditions. The company's primary investigational product was INOpulse, a distinctive system designed for the pulsatile delivery of nitric oxide, aimed at addressing pulmonary hypertension. This platform was previously undergoing a pivotal Phase 3 clinical trial for pulmonary hypertension linked to fibrotic interstitial lung disease. However, top-line results released in June 2023 indicated that the REBUILD study did not achieve its primary endpoint regarding an improvement in moderate to vigorous physical activity. Consequently, Bellerophon Therapeutics announced the cessation of all INOpulse development programs, which also included those in earlier stages for pulmonary hypertension associated with chronic obstructive pulmonary disease and sarcoidosis. Following these developments and subsequent workforce reductions, the company's board of directors filed a plan to liquidate the company, leading to the delisting of its shares from Nasdaq in October 2023. The company, which originated as Ikaria Development LLC before adopting the Bellerophon Therapeutics name in January 2014, was established in 2009 and had its headquarters in Warren, New Jersey.
Why Is Bellerophon Therapeutics (BLPH) Stock Down 34% Today?
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July - Cibus (NASDAQ:CBUS), Bellerophon Therapeutics (NASDAQ:BLPH)
Bellerophon (BLPH) Down 87% as Lung Disease Candidate Fails
Is Bellerophon Therapeutics (BLPH) Outperforming Other Medical Stocks This Year?
Bellerphon Therapeutics stock plunges toward record selloff after lung disease treatment performs worse than placebo in late-stage trial
Why Is Bellerophon Therapeutics (BLPH) Stock Down 79% Today?
5 Stocks With Recent Price Strength Amid March Rally
Bellerophon Therapeutics (BLPH) Is a Great Choice for 'Trend' Investors, Here's Why
Here's Why Momentum in Bellerophon Therapeutics (BLPH) Should Keep going
How to Find Cheap Penny Stocks to Make Money Trading
5 Hot Penny Stocks Exploding After News This Week
Bellerophon (BLPH) Receives FDA Acceptance to Reduce Study Size
Bellerophon to Present at the H.C. Wainwright BioConnect 2022 Conference
Bellerophon Therapeutics Stock (BLPH): Why The Price Jumped
These Biotech Penny Stocks Exploded Today, Here's Why
Bellerophon Therapeutics (BLPH) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Bellerophon to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Why Entera Bio, Orphazyme, Bellerophon Are Moving Today
8 Hot Biotech Penny Stocks For Your July 2021 Watch List
Bellerophon to Present at the Jefferies Virtual Healthcare Conference